New pill aims to fight silent liver scourge
Disease control
Not yet recruiting
This study is testing if a new oral drug called SNP-610 can help control non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease that can lead to scarring and liver failure. About 80 adults in Taiwan with confirmed NASH will take either the drug or a placebo p…
Phase: PHASE2 • Sponsor: Sinew Pharma Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC